MIRAMAR BEACH, Fla. — (BUSINESS WIRE) — January 13, 2015 — Rainbow Coral Corp. (OTCBB: RBCC) executive leadership will preview the latest innovations and network with top biotechnology investors this week at Biotech Showcase 2015 in San Francisco, where the company’s joint venture partner, Nano3D Biosciences (n3D) will exhibit the revolutionary Bio-Assembler device.
Biotech Showcase is an investor and partnering conference devoted to providing biotechnology companies with an opportunity to present new ideas and products to investors and pharmaceutical executives from around the world. One of the industry's largest annual healthcare investor conferences, the event will make for an ideal platform to raise awareness about the Bio-Assembler, the world’s first commercially available 3D bioprinting system designed for high throughput and high-content drug screening.
“Biotech Showcase 2015 will bring together cutting-edge technology with eager investors looking for the next big thing, creating potentially highly lucrative partnering opportunities for our company,” said RBCC CEO Kimberly Palmer. “We’re extremely pleased that n3D will be showcasing the extraordinary capabilities of the Bio-Assembler here in San Francisco. It’s the most affordable and easy-to-use technology of its kind on the market today.”
For months, RBCC and n3D have been focused on raising millions of dollars to further market and develop the Bio-Assembler and other 3D bioprinting technology around the globe. The electronic device uses biocompatible magnetic nanoparticles to levitate cells, allowing them to grow into 3D structures much faster more simply than competing technologies.
Through its biotech subsidiary, Rainbow Biosciences, RBCC markets and develops new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). Rainbow Biosciences acquired an equity interest in n3D in 2012.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Rainbow Coral Corp.
Kimberly Palmer, 850-269-7230
President and CEO